Layout Table~~~~1427~1427~~

The World Diabetes Market, 2005-2011~
Published by Visiongain, March 2006

Diabetes effects approximately 170 million people worldwide and is increasing, with the WHO predicting 300 million diabetics by 2025. The US alone has 20.8 million people suffering with diabetes. This equates to approximately 6% of the population. It was the 6th most common cause of death as recorded on US death certificates.

~Published by Visiongain, March 2006

Diabetes effects approximately 170 million people worldwide and is increasing, with the WHO predicting 300 million diabetics by 2025. The US alone has 20.8 million people suffering with diabetes. This equates to approximately 6% of the population. It was the 6th most common cause of death as recorded on US death certificates.

The Global Diabetes drugs treatment market was valued of $15 billion in 2005. Oral anti-diabetics were the leading category of drugs - $8.19 billion - and showed a growth rate of 6.3% from the total global sales in 2004. The total sales for insulin products increased by 16.5% to total global sales of $6.83 billion in 2004.

Key Market for the Future…

Visiongain predicts that the retail market for diabetes medications will continue to show significant growth for what is an already large market. Actos from Takeda is the leading oral anti-diabetic product and appears set to retain this status. However, it is co-marketed with Eli Lilly which has new products to make available. Lantus from Sanofi-Aventis is the leading insulin product. But there are three new products available, including the world’s first inhaled insulin product – Exubera from Pfizer.

Why you should buy this report:

* Diabetes treatment is a leading therapeutic area and is about to become even more important.
* The world’s first inhaled insulin product has just been approved to the world’s largest pharmaceutical company. This report will help you to assess just what impact that this is likely to have.
* The market is dominated by a Japanese product – is this a sign of things to come from a previously struggling side of the industry?
* Visiongain has taken the latest available financial statistics and forecast revenue figures for all the leading products.
* The report contains analysis of the pipeline and potential blockbuster products of the next five years.

Table of Contents ~The World Diabetes Market, 2005-2011 (Single user License PDF)|944|The World Diabetes Market, 2005-2011 (Department License PDF)|945|The World Diabetes Market, 2005-2011 (Company wide license PDF)|946|~1427~3025~~

The Global Endocrine Pharmaceutical Market~
Published by Visiongain, March 2005

This 170+ paged report features 50+ tables, 20+ graphs and 20+ charts, news, insights, the very latest developments and an in-depth review of the endocrine market with up to date analysis. This report is a vital addition to gaining an understanding of this lucrative area of the pharmaceutical market, and will give your company 'the edge' of your competitors. You can not afford to be without this latest report from visiongain.~
Published by Visiongain, March 2005

Today, the global endocrine pharmaceutical market is a highly lucrative multi-billion dollar business, but, can you confidently answer the following?

What endocrine diseases will be successful?
What endocrine diseases will lose out?
What area of endocrine do you need to invest in?
Which areas of endocrine do you need to avoid?
Who are the key players in the endocrine market?
How much is the total global endocrine market worth today and in the future?
What are the major changes to the endocrine market?
Are there any newcomer's of importance?
What is in the endocrine pipeline?
Know the answer to all these questions and much more in visiongains latest global endocrine pharmaceutical market report.

Visiongain values the total global endocrine market at $43.2bn in 2005, a growth of 13.5% from 2004. The endocrine diseases market is expected to grow over 100% over the forecast period, to produce revenues in 2010 of just under $70bn. Major changes of the market are expected over the forecast period, such as the arrival of insulin delivery technologies and massive losses of the hypothyroidism market due to increasing generic competition.

For in-depth analysis of these changes it is vital that you purchase Endocrine 2005. Designed as an essential business aid, Endocrine 2005 provides a thorough evaluation of the market for you to keep ahead of your competitors.

Learn about the four therapeutic area major earners of the industry:

1) Hypertension
2) Diabetes
3) Osteoporosis
4) Infertility

In addition, Endocrine 2005 also features market analysis of the following:

- Growth Hormone Replacement
- Acromegaly
- Hypothyrodism and Hyperthyrodism

Why You Must Buy This Report
This 170+ paged report features 50+ tables, 20+ graphs and 20+ charts, news, insights, the very latest developments and an in-depth review of the endocrine market with up to date analysis. This report is a vital addition to gaining an understanding of this lucrative area of the pharmaceutical market, and will give your company 'the edge' of your competitors. You can not afford to be without this latest report from visiongain.

Sample Page 1

Sample Page 2~The Global Endocrine Pharmaceutical Market (Single user License PDF)|344|The Global Endocrine Pharmaceutical Market (Department License PDF)|596| The Global Endocrine Pharmaceutical Market (Company wide license PDF)|973|~1427~1817~~